Drugs / RM-1995
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05220748 | Mar 2022 → Jan 2023 | head and neck squamous cell carcinoma, skin squamous cell carcinoma | Rakuten Medical, Inc. | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RM-1995 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05220748 ↗ |
| Route | Intravenous | “RM-1995 will be administered by intravenous (IV) infusion” NCT05220748 ↗ |